Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.

Current pharmaceutical design - 1 Jan 2020

Baatjes Karin, Peeters Armand, McCaul Micheal, Conradie Maria M, Apffelstaedt Justus, Conradie Magda, Kotze Maritha J

Abstract excerpt

BACKGROUND: Significant individual variation in bone loss associated with aromatase inhibitors (AIs) emphasizes the importance of identifying postmenopausal breast cancer patients at high risk for this adverse effect. The study explores the clinical relevance of genetic variation in the Cytochrome P450 19A1 (CYP19A1) gene in a subset of South African patients during the first year of taking AIs for estrogen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Density

Share to Breast Neoplasms

Share to Follow-Up Studies

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Postmenopause

Source

Identifiers

PMID: 32900345
DOI: 10.2174/1381612826666200908141858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.PMID 32900345Read ↗

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.Semantic proximity Read ↗

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.Semantic proximity Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.Semantic proximity Read ↗

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Semantic proximity Read ↗

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Genetic prediction of long-term effects of aromatase inhibition on cancer and non-neoplastic disease riskSemantic proximity Read ↗

Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.Semantic proximity Read ↗

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.Semantic proximity Read ↗

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.Semantic proximity Read ↗

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.